Dr. Doug Helmersen

Dr. Doug Helmersen

Position in Division

Clinical Respirologist

Clinical and Research Interests

Graduating School and Year

U of Calgary (1996)

Residency/Fellowship

Post Fellowship Training

Publications (Last 5 Years)

  1. Early Post-Transplant Smooth Muscle Neoplasia of the Colon Presenting as Diminutive Polyps : A Case Complicating PTLD. S. Medlicott, S.Devlin, D.Helmersen, A.Yilmaz, A.Mansoor. Intern J Surg Pathol 2006; 14(2):155-61
  2. Lymphangioleiomyomatosis (LAM) Presenting as Severe Pulmonary Hypertension. P.MacEachern, S.Viner, F.Green, D.Helmersen. CHEST 2004; 126 (4):978-9S
  3. Sildenafil Treatment of Primary Pulmonary Hypertension. K. Laupland, D.Helmersen, D. Zygun, S.Viner. Can Resp J 2003; 10(1): 48-50
  4. Positive Anti-PR3 (ANCA) and Anti-GBM Antibody Tests Associated with Pulmonary Tuberculosis. D.Helmersen, M.Ainslie, D.Zuege, K.Rimmer, R.Cowie. CHEST 2001;120(4):342S

Abstracts

  1. Characteristics and Long Term Outcome of Southern Alberta Patients with Chronic Thromboembolic Pulmonary Hypertension. J.Davies, P.MacEachern, S.Viner, G.Ford, D.Helmersen. Proceedings of the American Thoracic Society 2006 (3):A167
  2. Pulmonary Thromboendarterectomy (PTE) Following Splenectomy : Patient Characteristics and Outcomes. D. Helmersen, W. Auger, P.Fedullo, K.Kerr, N.Kim, M.Madani, S.Jamieson. Am J Resp Crit Care Med. 2004;169 (7):A666.

Book Chapters

  1. Endothelin Receptor Antagonists. D.Helmersen, R.Channick, L.Rubin. In : Pulmonary Circulation:Diseases and their Treatment, 2nd Edition. A.J.Peacock and L.J. Rubin Eds. Edward Arnold Publishers. London. (2004)
  2. Risk Factors for COPD. D.Helmersen, G.Ford, S.Bryan, A.Jone, C.Little. In : Comprehensive Management of COPD. J.Borbeau Ed. BC Decker Inc. (2002)
Dr. Doug Helmersen's Hobby